Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
HLN · against 69 other Healthcare companies of similar size
Ranked #9 of 70 · scores higher than 88% of peers
Bars: peers in each 10-point band of the valuation score11 peers with a valuation score of 70–79, including HLN · Click a bar to see the companies
Mainly thanks to its earnings yield and EBITDA yield, which are stronger than most Healthcare peers.
| Metric | HLN | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 66 reported | 5.4% | 3.0% | 89% | 30% | |
| EBITDA yieldHigher is better · 71 reported | 7.8% | 6.0% | 80% | 50% | |
| Free cash flow yieldHigher is better · 49 reported | Not reported | 3.8% | — | — | 20% |
| Book yieldHigher is better · 66 reported | 56.1% | 20.8% | 91% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.5B USD | 95 | 60 | |
| 2 | 4.61T JPY (≈$31.3B) | 93 | 76 | |
| 3 | 6.17T JPY (≈$42.0B) | 86 | 70 | |
| 4 | 45.9B USD | 84 | 61 | |
| 5 | 34.3B USD | 83 | 57 | |
| 6 | 23.8B USD | 82 | 84 | |
| 7 | 3.53T JPY (≈$24.0B) | 78 | 68 | |
| 8 | 27.5B EUR (≈$30.2B) | 76 | 60 | |
| 9 | 38.9B USD | 75 | 56 | |
| 10 | 63.0B USD | 74 | 65 | |
| 10 | 36.4B USD | 74 | 50 | |
| 12 | 534.1B HKD (≈$68.4B) | 72 | 75 | |
| 12 | 48.5B EUR (≈$53.4B) | 72 | 53 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score